• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

    37.45 -1.28 (-3.30%)
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 377,299
    Open 38.61
    Bid (Size) 37.48 (1)
    Ask (Size) 38.33 (5)
    Prev. Close 38.73
    Today's Range 37.38 - 39.30
    52wk Range 25.57 - 75.02
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
    Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
    Via MarketBeat
    The 3 Smartest Biotech Stocks to Buy With $5K Right Now
    With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. 
    Via InvestorPlace

    Performance

    YTD
    -7.28%
    -7.28%
    1 Month
    -28.99%
    -28.99%
    3 Month
    -5.24%
    -5.24%
    6 Month
    -7.28%
    -7.28%
    1 Year
    -9.98%
    -9.98%

    More News

    Read More
    Could Structure Therapeutics Become the Next Novo Nordisk?
    Via The Motley Fool
    Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
    Via Investor's Business Daily
    Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
    Via The Motley Fool
    Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
    Via Investor's Business Daily
    Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
    Via The Motley Fool
    Top Names Performance Update - Saturday, June 8
    Via Talk Markets
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Via Talk Markets
    Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    The 3 Most Undervalued Biotech Stocks to Buy in June 2024
    Via InvestorPlace
    Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
    Via Investor's Business Daily
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
    Via InvestorPlace
    This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
    Via Benzinga
    GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.